Amarin Announces Promotion of Aaron Berg to Senior Vice President, Marketing and Sales
February 04 2014 - 6:00AM
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company
focused on the commercialization and development of therapeutics to
improve cardiovascular health, announced today that industry
veteran, Aaron Berg, has been promoted to Senior Vice President,
Marketing and Sales.
With more than 25 years of industry experience, Mr. Berg has
significant marketing and sales experience, including six years at
Kos Pharmaceuticals where as Vice President of Marketing and Sales
his contributions to the commercial success of Niaspan® helped lead
to the acquisition of Kos in 2006 by Abbott Laboratories for $3.6
billion. Before joining Kos Pharmaceuticals, Mr. Berg began his
pharmaceutical industry career as a sales representative with
Bristol-Myers Squibb followed by 10 years of increasing commercial
responsibility at Schering-Plough before being recruited by
GlaxoSmithKline to help build its then newly launched diabetes
franchise. After Kos Pharmaceuticals, Mr. Berg's commercial
and business development expertise in lipid therapy led
Essentialis, a development-stage company focused on triglyceride
management, to appoint Mr. Berg as President and CEO where he
remained until he was recruited by Amarin at the end of
2012. Mr. Berg joined Amarin as Vice President, Marketing and
Managed Care, which responsibilities he assumed from the time of
launch of Vascepa® in early 2013.
"On behalf of Amarin and its Board of Directors, it is with
great pleasure that I announce the promotion of Aaron to this
important expanded role," stated John F. Thero, President and Chief
Executive Officer of Amarin. "Aaron's experience, leadership and
dedication since joining Amarin have been crucial factors in
establishing the sales focus, product messaging and managed care
wins that position Vascepa for further growth. I have the
utmost confidence in Aaron's ability to build on these efforts in
leading Amarin's commercial team positively forward in its second
year of Vascepa commercialization."
"I am proud to be a member of the Amarin team and confident in
the continued growth of Vascepa sales," said Mr. Berg. "Vascepa
provides physicians and their patients with a valuable offering for
the treatment of severe hypertriglyceridemia. It is an
exciting time to be at Amarin."
About Vascepa® (icosapent ethyl)
capsules
Vascepa® (icosapent ethyl) capsules, known in scientific
literature as AMR101, is a highly pure-EPA omega-3
prescription product in a 1 gram capsule.
Indications and Usage
- Vascepa (icosapent ethyl) is indicated as an adjunct to diet to
reduce triglyceride (TG) levels in adult patients with severe (≥500
mg/dL) hypertriglyceridemia.
- The effect of Vascepa on the risk for pancreatitis and
cardiovascular mortality and morbidity in patients with severe
hypertriglyceridemia has not been determined.
Important Safety Information for Vascepa
- Vascepa is contraindicated in patients with known
hypersensitivity (e.g., anaphylactic reaction) to Vascepa or any of
its components and should be used with caution in patients with
known hypersensitivity to fish and/or shellfish.
- The most common reported adverse reaction (incidence > 2%
and greater than placebo) was arthralgia (2.3% for Vascepa, 1.0%
for placebo).
FULL VASCEPA PRESCRIBING INFORMATION CAN BE FOUND
AT WWW.VASCEPA.COM.
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health. Amarin's product development program
leverages its extensive experience in lipid science and the
potential therapeutic benefits of polyunsaturated fatty acids.
Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is
a patented, ultra pure omega-3 fatty acid product comprising not
less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit
www.amarincorp.com.
Forward-looking statements
This press release contains forward-looking statements,
including statements about Amarin's expectations for commercial
growth. These forward-looking statements are not promises or
guarantees and involve substantial risks and uncertainties. In
particular, as disclosed in its previous filings with the U.S.
Securities and Exchange Commission, Amarin's ability to effectively
commercialize Vascepa will depend in part on its ability to create
market demand for Vascepa through education, marketing and sales
activities, to achieve market acceptance of Vascepa, to receive
adequate levels of reimbursement from third-party payers, to
develop and maintain a consistent source of commercial supply at a
competitive price, and to obtain and maintain patent protection and
regulatory exclusivity. A further list and description of
these risks, uncertainties and other risks associated with an
investment in Amarin can be found in Amarin's filings with the U.S.
Securities and Exchange Commission, including its most recent
Quarterly Report on Form 10-Q. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.
Availability of other information about
Amarin
Investors and others should note that we communicate with our
investors and the public using our company website
(www.amarincorp.com), our investor relations website
(http://www.amarincorp.com/investor-splash.html), including but not
limited to investor presentations and investor
FAQs, Securities and Exchange Commission filings, press
releases, public conference calls and webcasts. The information
that we post on these channels and websites could be deemed to be
material information. As a result, we encourage investors, the
media, and others interested in Amarin to review the information
that we post on these channels, including our investor relations
website, on a regular basis. This list of channels may be updated
from time to time on our investor relations website and may include
social media channels. The contents of our website or these
channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Niaspan® is trademark of AbbVie Inc.
CONTACT: Joseph Bruno
Investor Relations and Corporate Communications
Amarin Corporation
In U.S.: +1 (908) 719-1315
investor.relations@amarincorp.com
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024